Safety and immunogenicity of 2-dose Ebola vaccine regimen with Ad26.ZEBOV and MVA-BN-Filo in a phase II clinical trial in Europe

The Ad26, MVA vaccine regimens were found to be well tolerated and immunogenic. Binding antibody responses persisted at least up to one year post-dose 1. This study supports the further development of Ad26, MVA heterologous 2-dose vaccination for the prevention of Ebola Virus Disease